Karyopharm Therapeutics Inc. 8-K

What Happened
Karyopharm Therapeutics Inc. (KPTI) filed an 8‑K reporting results of its May 21, 2026 annual meeting and related Board/Compensation Committee actions. Stockholders approved an amendment to the 2022 Equity Incentive Plan adding 3,000,000 shares. The Board/Compensation Committee approved a broad-based retention program on May 22, 2026 and granted performance-based restricted stock unit (PSU) awards effective May 31, 2026 to employees including the CEO, CFO and other named executives.

Key Details

• Annual meeting date: May 21, 2026; 8‑K filed May 28, 2026.
• Equity Plan amendment: stockholders approved +3,000,000 shares for the 2022 Equity Incentive Plan (vote: 10,474,681 for; 953,411 against; 2,593 abstain; 5,410,881 broker non‑votes).
• Retention PSUs: the program grants two performance PSU awards (First PSU vests on a clinical milestone; Second PSU vests on two milestones — 50% on each — and also requires continued service and shareholder approval of additional plan shares by May 31, 2027). Total PSUs to be granted under the program: 3,838,380. Notable grants include:
  • Richard Paulson (President & CEO): 343,000 PSUs for each award (686,000 total).
  • Reshma Rangwala (EVP, CMO): 150,000 PSUs for each award (300,000 total).
  • Lori Macomber (EVP, CFO): 130,000 PSUs for each award (260,000 total).
  • Stuart Poulton (EVP, Chief Development Officer): 130,000 PSUs for each award (260,000 total).
• Board also approved a future plan amendment to add 950,000 more shares subject to stockholder approval on or before May 31, 2027.
• Other shareholder votes at the meeting: approved a 1,400,000‑share increase to the ESPP (11,221,920 for; 203,702 against), advisory approval of executive compensation (10,025,198 for; 1,388,274 against), election of Class I directors Barry E. Greene and Christy J. Oliger, and ratification of Ernst & Young LLP as auditor (16,695,588 for).

Why It Matters
These actions increase the company’s equity run‑way for employee incentives and establish a large, performance‑based retention program tied to clinical and other milestones. For investors, the plan increases and PSU grants can dilute share count over time if awards vest and are settled in stock; however, the grants are performance‑based, linking potential dilution to specific milestones. The Board’s additional request to add 950,000 shares is conditioned on future stockholder approval, so further dilution is contingent on that vote.